Gen-Probe downgraded to Neutral from Outperform at RW Baird Baird downgraded Gen-Probe (GPRO) after the company agreed to be acquired by Hologic (HOLX) for $82.75 per share in cash, or $3.7B. Target $82.75.
News For GPRO From The Last 14 Days
Check below for free stories on GPRO the last two weeks.
